RE:RE:RE:hyping THHere is the Google translate version of the article by TVA Nouvelles. What Beliveau and Levesque said is more nuanced than what the host said or what the title of the article is. Both never talked about a cure, but of a potential new weapon in the artillery.
Soon a cure for Cancer?
Every day, there are 158 cancer diagnoses in Quebec, and 65 people die from it. If it's the number one killer in the province, a breakthrough could make a difference.
"We are very enthusiastic because I have worked in oncology for 35 years, and this is the first time that I have seen results," says Dr. Richard Bliveau, researcher and doctor in biochemistry. “Often we imagine something in research, but experience shows us that we have to adapt our hypothesis. With this platform, we didn't have any surprises, that's what is amazing, the predictions we made were pretty much all confirmed. This is the dream of the researcher. "
Paul Lvesque, CEO of Theratechnologies, is as optimistic as Mr. Bliveau. "I defer to the American investors who looked at what we have and who were amazed at the quality of the data in the preclinical phase," he says.
Neutralize the enemy
We must find a cancer treatment more effective than chemotherapy, it is the sinews of war, according to the researcher.
"When you attack an enemy, you attack it with its weak points, so what we have identified is one of the weak points of the cancer cell," explains Dr. Bliveau. “We are using that entry route there for the attack. It's like a missile guided by GPS technology, you target the explosive charge directly where the missile needs to explode, so the collateral damage is lower. "
If Quebec succeeds in neutralizing cancer or in finding a solution that would be part of the heavy artillery in the fight against the disease, that would be to the credit of the people who identified the problem in the laboratory and who had it. developed subsequently, according to Mr. Lvesque.
"Fortunately we have these skills to do it, then if we get to the marketing, we'll see if we can commercialize this on a global scale," he adds.
Since research and laboratory equipment are expensive, one of the main challenges in the deployment of oncology research is funding.
"But as long as the science continues to move in the same direction with the clinical data that we have seen, as the data becomes more convincing, the funding will follow," notes Dr. Lvesque.
Mr. Bliveau points out that the project has received approval from the Food and Drug Administration (FDA), which is rare and remarkable, according to him. “It gives us a tactical and strategic advantage for development,” he says.
"Cancer is the number one public enemy, I think that everything we do in research to counter this enemy and reduce its impact is important and I think that this platform will reduce this impact."
SPCEO1 wrote: I don't speak French, so I can't understand what the host said but from your description, it certainly sounded way over the top. But TH tweeted it out. Do you think they should not have done so?
jfm1330 wrote: No false hope given by Levesque and Beliveau, but a huge false hope given by the host Pierre-Olivier Zappa. TH1902 will not be a cure for cancer. Maybe in the future, in favorable cases some patients will be cured, but that already exist. Also, maybe in the future TH19P01 with another cytotoxic agent, better than docetaxel could be more poweful, but we are far from that right now. Also, you cannot talk of cancer and a cure for it as if cancer was a single illness. Cancers are a family of different diseases with a single trait, genetic deregulation of cell propagation. But this deregulation is caused by many different mutations. So impossible to treat or even cure cancer with a single approach. So to talk about a cure for cancer was pure bullsh*t on the part of the host. Sensationalism at its best, but hey, some wants promotion, there you have it!
princess77 wrote: Finally TH being talked up by the company, I appreciate it. I don't see any false hope being given in that article. They are excited, finally.